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Background: The efficacy and safety of apremilast were assessed in patients with psoriatic arthritis (PsA) in three
phase III clinical trials with similar designs (PALACE 1, 2, and 3).
Methods: Following a 24-week, randomized (1:1:1 to apremilast 30 mg twice daily, 20 mg twice daily, or placebo),
double-blind phase and a 28-week blinded active treatment phase, patients could receive apremilast in open-label
extension studies for an additional 4 years. Eligible adult patients had active PsA for ≥ 6 months and three or more
swollen joints and three or more tender joints despite prior treatment with disease-modifying anti-rheumatic drugs.
Results: A total of 1493 randomized patients received one or more doses of study medication (placebo: n = 496;
apremilast 30 mg twice daily: n = 497; apremilast 20 mg twice daily: n = 500). In patients continuing apremilast
treatment, response was sustained without new safety issues. At week 260, 67.2% of remaining patients achieved
an ACR20 response, and 44.4% and 27.4% achieved ACR50 and ACR70 responses, respectively. Among patients with
baseline enthesitis and dactylitis, 62.4% achieved a Maastricht Ankylosing Spondylitis Enthesitis Score of 0 and 80.9%
achieved a dactylitis count of 0, respectively. In patients who had ≥ 3% baseline psoriasis body surface area
involvement, 43.6% achieved ≥ 75% reduction from the baseline Psoriasis Area and Severity Index scores. The most
commonly reported adverse events (AEs) were diarrhea, nausea, headache, upper respiratory tract infection, and
nasopharyngitis, with most diarrhea and nausea AEs occurring within the first 2 weeks of treatment and usually
resolving within 4 weeks. Reported rates of depression during the study were low (≤ 1.8%). The majority of patients
maintained their weight within 5% of baseline during the study. No new safety concerns or increases in the incidence
or severity of AEs were observed over the long term.
Conclusions: Apremilast maintained clinical benefit and a favorable safety profile for up to 5 years among patients
with PsA.
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Apremilast, an oral phosphodiesterase 4 inhibitor, has
been proven effective in patients with psoriatic arthritis
(PsA) [1–3]. Apremilast was studied for the treatment of
PsA in three similarly designed, phase III studies (Psoriatic
Arthritis Long-term Assessment of Clinical Efficacy
[PALACE] 1, 2, and 3) that enrolled disease-modifying
anti-rheumatic drug (DMARD)-experienced patients [1–3].
These studies included an open-label extension phase to
evaluate the effects of long-term exposure to apremilast.
We now report the final long-term findings for PALACE 1,
2, and 3 in patients with active PsA who received apremi-
last for up to 260weeks.
Methods
Study design
PALACE 1, 2, and 3 were phase III, multicenter, random-
ized, double-blind, placebo-controlled studies. The three
studies used the same study design and have been previ-
ously described [1–3]. Briefly, each study comprised a
24-week, randomized, double-blind, placebo-controlled
phase; a 28-week blinded active treatment phase; and a
long-term, open-label extension phase for up to an add-
itional 4 years. Patients were randomly assigned at base-
line (1:1:1) to receive placebo, apremilast 30mg twice
daily, or apremilast 20mg twice daily. Patients random-
ized to placebo were re-randomized to apremilast 30mg
twice daily or 20mg twice daily at week 16 (early escape)
or week 24. Patients who completed 52 weeks of treat-
ment were eligible to enroll in the long-term extension for
apremilast treatment for an additional 4 years.
Patients
As previously described, patients were adults with active
PsA for ≥ 6 months who met the Classification Criteria
for Psoriatic Arthritis (CASPAR) [4] and had three or
more swollen joints and three or more tender joints des-
pite prior exposure to conventional or biologic
DMARDs [1–3]. Patients enrolled in PALACE 3 also
had active skin disease with at least one plaque psoriasis
lesion that was ≥ 2 cm in size [3].
Study outcomes
Efficacy assessments
Efficacy endpoints included rates of patients achieving
≥ 20% improvement in American College of Rheumatol-
ogy response criteria (ACR20) (primary endpoint),
ACR50, and ACR70 responses, modified for PsA using
the 76 swollen joint count (SJC) and 78 tender joint
count (TJC) (i.e., inclusion of distal interphalangeal
joints of the toes and carpometacarpal joints to total
joint counts) [5, 6]; changes from baseline in SJC and
TJC; proportions of patients achieving a Maastricht An-
kylosing Spondylitis Enthesitis Score (MASES) [7] of 0among those with enthesitis at baseline, and proportions
of patients achieving a dactylitis count of 0 among those
with dactylitis at baseline. Physical function assessments
included mean change from baseline and achievement of
a minimal clinically important difference (MCID) of ≥
0.35 [8] in the Health Assessment Questionnaire-Disa-
bility Index (HAQ-DI) score [9]. Skin involvement was
also assessed using ≥ 75% reduction from the baseline
Psoriasis Area and Severity Index (PASI-75) in patients
with psoriasis involving ≥ 3% of body surface area at
baseline.
Safety assessments
Safety assessments were conducted at scheduled visits dur-
ing each treatment phase and in the event of early termin-
ation/withdrawal and included collection of adverse events
(AEs) as well as physical examination and clinical labora-
tory findings. The AEs occurring after randomization were
classified using the Medical Dictionary for Drug Regulatory
Activities Classification System.
Statistical analyses
Data were pooled across the three studies. Efficacy data
were analyzed descriptively by time point using all avail-
able data; analyses through week 260 were based on
observed data without imputation for missing data.
Safety outcomes were analyzed descriptively for all pa-
tients who received one or more doses of apremilast and
are presented for the apremilast-exposure periods from
weeks 0 to ≤ 52 (relative to the first dose of apremilast),
weeks > 52 to ≤ 104, weeks > 104 to ≤ 156, weeks > 156
to ≤ 208, and weeks > 208.
Results
Patients
Across PALACE 1–3, 1493 patients were randomized
and received one or more doses of study medication
(placebo: n = 496; apremilast 30 mg twice daily: n = 497;
apremilast 20 mg twice daily: n = 500). Baseline patient
demographic and disease characteristics have been pre-
viously described [1–3] and were comparable across
treatment groups. Among patients randomized to apre-
milast 30 mg or 20 mg at baseline, 44.5% (221/497) and
42.4% (212/500) completed week 260, respectively.
Among patients randomized to placebo at baseline and
switched to apremilast 30 mg or 20 mg at week 16 or 24,
49.1% (110/224) and 41.8% (92/220) completed week
260, respectively. Of those who received apremilast 30
mg or 20 mg entering week 52, regardless of when initi-
ated (baseline, week 16, or week 24), 63.2% (331/524)
and 58.7% (304/518) completed 260 weeks, respectively.
A total of 684 patients had > 208 weeks of exposure to
apremilast (20 mg, n = 320; 30 mg, n = 364). Over the
apremilast-exposure period, the most commonly cited
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sent by patient (18.0%), lack of efficacy (17.6%), and ad-
verse event (11.9%). Other reasons for discontinuation
included lost to follow-up (2.6%), non-compliance (1.2%),
protocol violation (0.6%), death (0.5%), and “other” (3.3%).
Efficacy outcomes
Of patients receiving apremilast 30 mg twice daily, 55.3%
achieved an ACR20 response at week 52; at week 260,
67.2% of patients who continued apremilast treatment
achieved an ACR20 response. Similarly, ACR50 and
ACR70 responses were sustained over 260 weeks with
continued treatment (Fig. 1, Additional file 1: Table S1).
Mean SJC and TJC improved by 63.3% and 49.8% at
week 52, with improvements reaching 82.3% and 72.7%,
respectively, with continued treatment at week 260
(Fig. 2, Additional file 1: Table S1).
Among patients with enthesitis or dactylitis at base-
line, mean changes in MASES and dactylitis at week 260
were − 2.9 and − 2.8, respectively. The proportions of
those achieving a MASES of 0 or a dactylitis count of 0
increased over 52 weeks and were maintained through
week 260 with continued apremilast 30 mg treatment
(Fig. 3, Additional file 1: Table S1).
Improvements in physical function were maintained
through week 260 in patients who continued receiving
apremilast 30 mg twice daily, including mean change in
HAQ-DI and the proportion achieving a HAQ-DI MCID
≥ 0.35 (Fig. 4, Additional file 1: Table S1).
Among patients with plaque psoriasis involving ≥ 3%
of the body surface area at baseline, the proportion of
patients achieving PASI-75 response was generally55.3%
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Fig. 1 ACR responses in PsA patients receiving apremilast 30 mg up to 260
including the placebo-controlled phase, regardless of when the patients st
proportions of psoriatic arthritis (PsA) patients achieving ACR20, ACR50, or
represent 95% confidence interval (CI). n represents the number of patientsmaintained with continued treatment, with 43.6% of pa-
tients having a PASI-75 response at week 260 (Add-
itional file 1: Figure S1 and Additional file 1: Table S1).
Pooled results for apremilast 30 mg twice daily were
consistent with the results observed in the individual
studies for all outcomes, including ACR20 responses
(Additional file 1: Figure S2). Apremilast 20 mg twice
daily also demonstrated improvements in the signs and
symptoms of PsA (Additional file 1: Table S1).
Safety outcomes
Most AEs were mild or moderate in severity with both
apremilast doses over weeks 0 to ≤ 52. During weeks 0
to ≤ 52, AEs occurring in ≥ 5% of apremilast-exposed pa-
tients included diarrhea, nausea, headache, upper re-
spiratory tract infection, and nasopharyngitis. Most
diarrhea and nausea AEs were reported within the first
2 weeks of treatment and usually resolved within 4
weeks; the frequency of gastrointestinal AEs decreased
with longer apremilast exposure, and the frequency of
other common AEs decreased or remained stable with
prolonged exposure (Table 1).
No new safety concerns or increases in the incidence
or severity of AEs were seen with exposure over 260
weeks (Table 1). Discontinuations due to AEs during
weeks 0 to ≤ 52 occurred in 7.6% of combined apremi-
last patients. In the longer exposure periods, ≤ 2.5% of
patients discontinued treatment because of AEs. The
most frequently reported AEs leading to discontinuation
of apremilast were diarrhea, nausea, and headache and
were primarily reported during the 0- to ≤ 52-week
period (Table 2).63.3% 63.7%
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Fig. 2 SJC/TJC improvements in PsA patients receiving apremilast 30 mg up to 260 weeks. Data as observed. The analysis includes all patient
data, including the placebo-controlled phase, regardless of when the patients started taking apremilast (baseline, week 16, or week 24). The mean
percentage changes in swollen joint count (SJC) and tender joint count (TJC) for psoriatic arthritis (PsA) patients at study visits up to week 260
are shown. Error bars represent 95% confidence interval (CI). n represents the number of patients with data available at that time point
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of combined apremilast patients) during each of the five
apremilast-exposure periods. Infections and infestations
and musculoskeletal and connective tissue disorders
were the most common classes of serious AE. Each was
reported in ≤ 1.8% of combined apremilast patients
during each apremilast-exposure period. During the
placebo-controlled period, rates of major cardiac events,
malignant neoplasms, and serious opportunistic infec-
tions were comparable between placebo and apremilast37.7%
48.7%
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count of 0 at study visits up to week 260 are shown. Error bars represent 9
either MASES ≥ 1 or dactylitis count ≥ 1 at baseline and data available at th[1–3]. There was no increase in overall rates with
longer-term exposure.
In the placebo-controlled period, reports of depression
were rare but greater with apremilast compared with
placebo (1.2% vs 0.8%). Rates of depression during the
long-term study were low with combined rates of 1.7%,
1.8%, 1.5%, 1.6%, and 1.0% for apremilast reported across
the five periods examined. No completed suicides oc-
curred during the study. Attempted suicide was reported
by one patient during the weeks 0 to ≤ 5255.0%
60.2%
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Fig. 4 Improvements in physical function among PsA patients receiving apremilast 30 mg up to 260 weeks. Data as observed. The analysis
includes all patient data, including the placebo-controlled phase, regardless of when the patients started taking apremilast (baseline, week 16, or
week 24). The proportions of patients achieving a Health Assessment Questionnaire-Disability Index (HAQ-DI) minimal clinically important
difference (MCID) of ≥ 0.35 at study visits up to week 260 are shown. n represents the number of patients with data available at that time point
Kavanaugh et al. Arthritis Research & Therapy          (2019) 21:118 Page 5 of 8apremilast-exposure period (following a serious family
altercation) and one patient during the weeks > 52 to ≤ 104
apremilast-exposure period (history of depression,
bipolar affective disorder, physical/emotional abuse).
No suicide attempts were reported during the remaining
apremilast-exposure periods. The ranges of mean (me-
dian) weight changes were between − 1.34 kg (− 1.00 kg)
and − 0.92 kg (− 0.90 kg) with apremilast 30mg and −
1.36 kg (− 1.00 kg) and − 0.98 kg (− 0.40 kg) with apremi-
last 20mg across exposure periods, with the majority of
patients maintaining their weight within 5% of baseline
during the study. Weight loss > 5% was observed in 21.8%
(155/711) of apremilast 30mg patients and 21.0% (149/708)
of apremilast 20mg patients. Clinically important labora-
tory abnormalities were generally infrequent, transient,
and of similar incidence during all periods (Table 1).
Throughout the longer-term apremilast-exposure periods,
the majority of patients with normal baseline values for la-
boratory parameters evaluated continued to maintain
values within the normal range (Additional file 1: Table S2).
Discussion
In one of the largest cohorts of patients with active PsA,
treatment with apremilast was evaluated for up to 5
years in the phase III PALACE 1, 2, and 3 studies. More
than 40% of patients continued apremilast treatment in
the long-term extension studies through 260 weeks.
During the long-term open-label extension phases of
these studies, the population of patients who continued
apremilast treatment for 5 years maintained improve-
ments in signs and symptoms of PsA, including SJC,
TJC, and physical function. Enthesitis, dactylitis, and
psoriasis were also improved in patients with these man-
ifestations at baseline. Given that one third of patientsremaining on treatment at week 260 did not achieve an
ACR20 response, results suggest using outcome measures
other than ACR20 response criteria when evaluating PsA
disease activity. In a separate study characterizing the clin-
ical benefits associated with long-term apremilast treat-
ment in patients who did not achieve an ACR20 response
at week 104, significant improvements in core psoriatic
domains were observed despite the ACR20 non-response
[10, 11]. Taken together, this may explain why patients
who fail to achieve an ACR20 response continue on
long-term apremilast treatment.
Apremilast continued to demonstrate a favorable
safety profile in patients with active PsA who were previ-
ously treated with a DMARD and/or biologic therapies.
The rates and types of AEs were consistent throughout
the three PALACE studies, and no new safety signals
were observed across 5 years of apremilast treatment.
A limitation of these studies is that the impact of apre-
milast on structural disease progression was not assessed
in the PALACE clinical trial program. Importantly, the
results from this analysis indicated significant improve-
ments in the numbers of swollen and tender joints over
5 years of treatment. Given that improvements in joint
inflammation have been associated with the prevention
of structural damage [12], it is possible that high levels
of disease control among patients in the PALACE 1–3
studies may have been associated with inhibition of dis-
ease progression. A limitation of controlled clinical stud-
ies is the enrollment of patients with restricted eligibility
criteria, which may not represent the general population
of patients with PsA. Additionally, although open-label
extensions offer insight into the experience with a given
treatment in the population of patients who do remain
on therapy over the long term, efficacy results may be
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Table 2 Adverse events leading to discontinuation in > 2 patients in any single exposure period through 260 weeks of apremilast
treatment by treatment period
Patients, n (%) Apremilast-exposure period*
Weeks 0 to ≤ 52 Weeks > 52 to ≤ 104 Weeks > 104 to ≤ 156 Weeks > 156 to ≤ 208 Weeks > 208 to ≤ 260
30mg
twice daily
(n = 721)
20 mg
twice daily
(n = 720)
30 mg
twice daily
(n = 520)
20 mg
twice daily
(n = 508)
30 mg
twice daily
(n = 443)
20 mg
twice daily
(n = 422)
30 mg
twice daily
(n = 401)
20 mg
twice daily
(n = 366)
30 mg
twice daily
(n = 364)
20 mg
twice daily
(n = 320)
Nausea 16 (2.2) 8 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Diarrhea 15 (2.1) 6 (0.8) 1 (0.2) 0 (0.0) 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0)
Headache 11 (1.5) 4 (0.6) 0 (0.0) 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Vomiting 6 (0.8) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Dizziness 4 (0.6) 2 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Upper
abdominal
pain
3 (0.4) 4 (0.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0)
Migraine 3 (0.4) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Fatigue 3 (0.4) 2 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0)
*Includes all patients who received apremilast during the time interval relative to the start of apremilast treatment
Kavanaugh et al. Arthritis Research & Therapy          (2019) 21:118 Page 7 of 8biased by the discontinuation of patients due to the lack
or loss of response and absence of a control arm. Emer-
ging real-world evidence will provide more insight into
the use and effectiveness of apremilast in clinical
practice.
Conclusions
In this pooled analysis of three long-term extension
studies, apremilast continued to demonstrate a favorable
safety profile, with no new safety concerns identified,
and was generally well tolerated for up to 5 years. Pa-
tients who continued therapy demonstrated sustained,
clinically meaningful improvements in the signs and
symptoms across various domains of PsA as well as in
physical function.
Additional file
Additional file 1: Figure S1. PASI-75 response in PsA patients receiving
apremilast 30 mg twice daily up to 260 weeks. Figure S2. ACR20 re-
sponses in PsA patients receiving apremilast 30 mg twice daily up to
260 weeks across PALACE studies. Table S1. Efficacy outcomes at week
260 in patients with PsA treated with apremilast. Table S2. Clinically im-
portant shifts in select laboratory measurements among patients with
normal values at baseline. (DOCX 117 kb)
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